Retatrutide Beats Mounjaro With 22.1% Weight Loss in 48 Weeks
Updated
Updated · The Independent · Sep 1
Retatrutide Beats Mounjaro With 22.1% Weight Loss in 48 Weeks
3 articles · Updated · The Independent · Sep 1
Summary
A 38-trial analysis covering more than 25,000 participants found experimental Retatrutide cut body weight by 22.1%, topping tirzepatide in Mounjaro at 19%.
Retatrutide's edge appears tied to its three-hormone approach—targeting GLP-1, GIP and glucagon—to curb appetite, regulate blood sugar and raise energy burn.
Amycretin posted 23.9% weight loss after 36 weeks, while semaglutide drugs such as Wegovy and Ozempic delivered about 18%; oral options trailed, with Wegovy's pill at 15.5% after 68 weeks and orforglipron at 14.7% after 36 weeks.
Serious adverse events and deaths were rare across the studies, with gastrointestinal side effects common and no new safety concerns identified.
The authors said GLP-1-based therapies are effective for people without diabetes, with injectable and oral obesity treatments still expanding even as retatrutide remains unauthorized in the UK.
Could experimental triple-hormone drugs like retatrutide make current blockbuster weight-loss injections obsolete, or do hidden muscle-loss risks outweigh their record-breaking results?
With experimental pills promising massive weight loss without injections, what happens to our metabolism when we suddenly stop taking these powerful medications?
As new obesity drugs mimic multiple hormones to erase appetite, will this pharmaceutical revolution permanently alter human culture and our relationship with food?